Autologous Bone Marrow and BMP7 Treatment in the Necrosis in the Femoral Head of the Adult (BMP7)

May 2, 2018 updated by: University Hospital, Lille

Evaluation of the Efficiency of Autologous Bone Marrow no Concentrated to Associate at BMP7 Treatment of Necrosis of the Femoral Head of the Adult

The main objective of the study is to evaluate the effectiveness of the injection of bone marrow unconcentrated more R BMP 7 to repair necrosis of the femoral head with stage I-III classification FICAT.

Study Overview

Detailed Description

Rationale and Objectives Epiphyseal necrosis are common in young adults (2000 new cases per year in the Nord Pas -de- Calais region) resulting in severe functional impairment and disability . Drilling is the procedure most simple, but its effectiveness and safety are discussed ( fracture risk , long discharge period , success rates below 50 % until stage III). However, it can be optimized in two ways: 1) reducing morbidity and discharge period by reducing the diameter of the channel and percutaneous achievement , 2 ) increase efficiency , including coverage contribution of stem cells and osteogenic hormone . The purpose of this study is to test the effectiveness of the contribution of these elements to the healing necrosis .

Material, Method, and primary endpoint This is a prospective multicenter clinical trial randomized double-blind . The effect of addition of autologous bone marrow stem cells and BMP7 on healing necrosis is assessed by magnetic resonance imaging ( NMRI ) and is the primary endpoint . Patients are randomly assigned to two arms : 1 ) Group I: a simple drilling is practiced , 2 ) Group II : the drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 ( OP1 ) . Necrosis of the femoral head with stage I to III are retained Ficat (only stage III with a recess of less than 3 mm are used , corresponding I-III according to Steinberg ) . Forty patients are included in each arm . A IRMN practiced preoperatively and at 6 months and 2 years. Clinical evaluation will be continued up to 5 years in testing the survival rate ( criterion censorship = recovery by hip ) Expected results and possible implications In terms of radiological stabilization ( NMRI ) the effectiveness of single drilling necrosis stage I to III Ficat is 60 % ( non- stabilization or worsening of size). The hypothesis tested is a gain stabilization ( and / or recovery) of 20 % . The clinical efficacy of single drilling necrosis stage I to III Ficat is estimated at 50 % (50% recovery by prosthesis in 5 years) . The assumption is a 20% improvement in the rate of success of the intervention . Reducing morbidity due to technical modifications has been previously tested. If the assumption of success is reached, the indications of drilling could be reinforced especially for patients with multiple visceral defects usually supported on the websites of University Hospital of Lille and Amiens and CH Roubaix ( organ transplant or tissue , ethyl , .. ) .

Study Type

Interventional

Enrollment (Actual)

41

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lille, France, 59037
        • CHRU de LILLE - service d'orthopédie C

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient aged between 18 and 60 years male or female.
  • Necrosis of the femoral head stage I to III FICAT (stage III with depression of less than 3 mm)
  • Nontraumatic osteonecrosis
  • Patient can undergo general anesthesia or locoregional
  • Having given his consent
  • Able to understand the constraints of the study

Exclusion Criteria:

  • Refusing to participate in the study
  • Active infection at the site
  • Cancer changing
  • Pregnancy
  • Necrosis posttraumatic
  • Having already undergone surgery on the surgical site
  • Contraindication to the practice of NMRI
  • Contraindication to the use of OP1 (BMP7): collagen, arthritis, scleroderma, lupus
  • Patient participating in another ongoing study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bone Marrow +BMP7
The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1)
Placebo Comparator: Drilling
Group I: a simple drill is practiced

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Necrosis volume
Time Frame: 24 months
Varying the volume of necrosis in MRI, student test comparing the mean (independent samples).
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Merle d'aubigné hip score
Time Frame: 6 and 24 months
variation of functional score, according to the two groups, by ANOVA repeated measures
6 and 24 months
Measurement of radiographic stage variation between pre-operative and 24 months radiographies using concentric circles of Möse
Time Frame: 24 months
24 months
Comparison of hip survival by measuring the number of revisions for hip replacement in the 2 groups
Time Frame: 60 months
Hip survival (= no revision for hip replacement) will be assessed using Kaplan-Meier curves and Logrank test.
60 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Henri Migaud, MD, PhD, University Hospital, Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2005

Primary Completion (Actual)

May 1, 2017

Study Completion (Actual)

May 1, 2017

Study Registration Dates

First Submitted

November 12, 2014

First Submitted That Met QC Criteria

January 11, 2016

First Posted (Estimate)

January 13, 2016

Study Record Updates

Last Update Posted (Actual)

May 8, 2018

Last Update Submitted That Met QC Criteria

May 2, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 2005-0503
  • TC 183 (Other Identifier: therapy cellulaire number, ANSM)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aseptic Necrosis of Femur Head

Clinical Trials on Bone Marrow +BMP7

Subscribe